Published in Cell Growth Differ on March 01, 1994
Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. Mol Cell Biol (1995) 7.36
Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol (1996) 5.17
Cell cycle regulation of the activity and subcellular localization of Plk1, a human protein kinase implicated in mitotic spindle function. J Cell Biol (1995) 4.26
Molecular interaction map of the mammalian cell cycle control and DNA repair systems. Mol Biol Cell (1999) 3.41
Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk. Proc Natl Acad Sci U S A (1998) 2.33
Plk is a functional homolog of Saccharomyces cerevisiae Cdc5, and elevated Plk activity induces multiple septation structures. Mol Cell Biol (1997) 2.22
Cloning and characterization of a putative human serine/threonine protein kinase transcriptionally modified during anisotonic and isotonic alterations of cell volume. Proc Natl Acad Sci U S A (1997) 2.14
Essential function of the polo box of Cdc5 in subcellular localization and induction of cytokinetic structures. Mol Cell Biol (2000) 2.07
Polo-box domain: a versatile mediator of polo-like kinase function. Cell Mol Life Sci (2010) 1.85
Plk phosphorylation regulates the microtubule-stabilizing protein TCTP. Mol Cell Biol (2002) 1.82
Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem (2009) 1.57
The conserved mitotic kinase polo is regulated by phosphorylation and has preferred microtubule-associated substrates in Drosophila embryo extracts. EMBO J (1996) 1.45
Polo kinase: the choreographer of the mitotic stage? J Cell Biol (1996) 1.33
Constitutive expression of murine Sak-a suppresses cell growth and induces multinucleation. Mol Cell Biol (1996) 1.26
Polo-like kinase 1 depletion induces DNA damage in early S prior to caspase activation. Mol Cell Biol (2009) 1.25
PLK1 phosphorylates mitotic centromere-associated kinesin and promotes its depolymerase activity. J Biol Chem (2010) 1.24
Polo-like kinase, a novel marker for cellular proliferation. Am J Pathol (1997) 1.19
Association of polo-like kinase with alpha-, beta- and gamma-tubulins in a stable complex. Biochem J (1999) 1.08
The polo-box-dependent induction of ectopic septal structures by a mammalian polo kinase, plk, in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1999) 1.05
Expression and phosphorylation of fibroblast-growth-factor-inducible kinase (Fnk) during cell-cycle progression. Biochem J (1998) 1.01
The balance of Polo-like kinase 1 in tumorigenesis. Cell Div (2009) 1.00
Polo-like kinase 1 overexpression is an early event in the progression of papillary carcinoma. Br J Cancer (2004) 0.98
Coordinating cellular events during spermatogenesis: a biochemical model. Trends Biochem Sci (2009) 0.86
The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation. Acta Pharmacol Sin (2009) 0.84
A 3'UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1. Mol Cancer (2014) 0.82
RNA interference against polo-like kinase-1 in advanced non-small cell lung cancers. J Clin Bioinforma (2011) 0.78
Mitotic Kinases and p53 Signaling. Biochem Res Int (2012) 0.78
Volasertib for AML: clinical use and patient consideration. Onco Targets Ther (2015) 0.77
Augmented expression of Polo-like kinase 1 is a strong predictor of shorter cancer-specific overall survival in early stage breast cancer at 15-year follow-up. Oncol Lett (2016) 0.76
Regulation of PLK1 through competition between hnRNPK, miR-149-3p and miR-193b-5p. Cell Death Differ (2017) 0.75
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (1999) 9.22
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res (2004) 9.18
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. Ann Intern Med (1984) 6.45
Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells. Nature (1985) 6.41
Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (1992) 5.94
Requirement for c-ras proteins during viral oncogene transformation. Nature (1986) 5.24
The Salmonella invasin SipB induces macrophage apoptosis by binding to caspase-1. Proc Natl Acad Sci U S A (1999) 5.17
Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol (1991) 5.02
Studies on an acetate-fermenting strain of Methanosarcina. Appl Environ Microbiol (1978) 4.75
Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med (1984) 4.73
STUDIES ON THE MECHANISM OF RECOVERY IN PNEUMOCOCCAL PNEUMONIA : IV. THE MECHANISM OF PHAGOCYTOSIS IN THE ABSENCE OF ANTIBODY. J Exp Med (1946) 4.20
Growth and methanogenesis by Methanosarcina strain 227 on acetate and methanol. Appl Environ Microbiol (1978) 3.70
The fine specificity of antigen and Ia determinant recognition by T cell hybridoma clones specific for pigeon cytochrome c. Cell (1982) 3.38
Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med (1999) 3.18
A bacterial invasin induces macrophage apoptosis by binding directly to ICE. EMBO J (1996) 3.16
An unbiased signal-to-noise ratio measure for magnetic resonance images. Med Phys (1993) 2.83
Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. J Biol Chem (1998) 2.80
Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem (1996) 2.78
Biological and Immunological Properties of Encapsulated Strains of Staphylococcus aureus from Human Sources. Infect Immun (1970) 2.68
Chemokines and T lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation in vitro. J Immunol (1996) 2.62
Death in the AIDS patient: role of cytomegalovirus. N Engl J Med (1983) 2.61
Heat labile opsonins to pneumococcus. II. Involvement of C3 and C5. J Exp Med (1969) 2.38
Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest (1995) 2.29
Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol (2009) 2.27
Absence of the Lyt-2-,L3T4+ lineage of T cells in mice treated neonatally with anti-I-A correlates with absence of intrathymic I-A-bearing antigen-presenting cell function. J Exp Med (1985) 2.27
Heat labile opsonins to pneumococcus. I. Participation of complement. J Exp Med (1969) 2.24
Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. Am J Med (1985) 2.18
A gain-of-function mutation in the sodium channel gene Scn2a results in seizures and behavioral abnormalities. Neuroscience (2001) 2.14
Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun (1997) 2.14
Interleukin 2 receptors on human B cells. Implications for the role of interleukin 2 in human B cell function. J Exp Med (1985) 2.14
Relation of Surface Phagocytosis to the Fibrinous Character of Acute Bacterial Exudates. Science (1949) 2.08
Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest (1998) 2.06
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res (1993) 2.01
Intercellular Surface Phagocytosis. Science (1947) 1.92
Specific inhibition of c-myc protein biosynthesis using an antisense synthetic deoxy-oligonucleotide in human T lymphocytes. J Immunol (1988) 1.86
Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J Biol Chem (1995) 1.80
Quantitative evaluation of several partial Fourier reconstruction algorithms used in MRI. Magn Reson Med (1993) 1.76
Identification of distinct predominant epitopes recognized by myoglobin-specific T cells under the control of different Ir genes and characterization of representative T cell clones. J Immunol (1984) 1.75
Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci U S A (1999) 1.72
Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood (2001) 1.71
Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol (1998) 1.70
Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol (1996) 1.70
Peripheral clonal elimination of functional T cells. Science (1990) 1.69
p53 mutation is associated with progression in follicular lymphomas. Blood (1993) 1.69
Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy. Blood (1992) 1.66
Murine syngeneic mixed lymphocyte response. I. Target antigens are self Ia molecules. J Exp Med (1981) 1.65
Clonal analysis of the major histocompatibility complex restriction and the fine specificity of antigen recognition in the T cell proliferative response to cytochrome C. J Immunol (1983) 1.63
Ras mediates translation initiation factor 4E-induced malignant transformation. Genes Dev (1992) 1.62
The relationship between immune interferon production and proliferation in antigen-specific, MHC-restricted T cell lines and clones. J Immunol (1983) 1.61
Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest (1998) 1.61
Lymphomas: MR imaging contrast characteristics with clinical-pathologic correlations. Radiology (1990) 1.60
A missense mutation in the sodium channel Scn8a is responsible for cerebellar ataxia in the mouse mutant jolting. J Neurosci (1996) 1.59
Polo-like kinase is required for the fragmentation of pericentriolar Golgi stacks during mitosis. Proc Natl Acad Sci U S A (2001) 1.59
Isolation of HTLV-transformed B-lymphocyte clone from a patient with HTLV-associated adult T-cell leukaemia. Nature (1984) 1.58
Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res (1998) 1.57
The control of chemotherapy-induced emesis. Ann Intern Med (1981) 1.55
Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol (1986) 1.55
Glass needle-mediated microinjection of macromolecules and transgenes into primary human blood stem/progenitor cells. Blood (2000) 1.55
Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J Natl Cancer Inst (1993) 1.54
Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol (1991) 1.53
T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest (1996) 1.53
Kappa B site-dependent activation of the interleukin-2 receptor alpha-chain gene promoter by human c-Rel. Mol Cell Biol (1992) 1.52
Small noncleaved cell lymphoma associated with florid epithelioid granulomatous response. A clinicopathologic study of seven patients. Am J Surg Pathol (1993) 1.51
Gene complementation. Neither Ir-GLphi gene need be present in the proliferative T cell to generate an immune response to Poly(Glu55Lys36Phe9)n. J Exp Med (1980) 1.49
Growth hormone as an immunomodulating therapeutic agent. Immunol Today (2000) 1.48
Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. J Clin Oncol (1993) 1.46
Hodgkin's disease following non-Hodgkin's lymphoma. A clinicopathologic and immunophenotypic study of nine cases. Am J Surg Pathol (1993) 1.45
Lymphocytic lymphoma of intermediate differentiation--mantle zone lymphoma: a distinct subtype of B-cell lymphoma. Hum Pathol (1987) 1.44
Distribution of misonidazole in human tumours and normal tissues. Br J Cancer (1979) 1.43
Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood (1994) 1.43
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
[Hemodynamic impact of thrombolytic therapy in acute pulmonary thromboembolism]. Arq Bras Cardiol (1995) 1.40
Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer (1990) 1.40
Inhibition of early murine hemopoietic progenitor cell proliferation after in vivo locoregional administration of transforming growth factor-beta 1. J Immunol (1989) 1.39
What's the deal with follicular lymphomas? J Clin Oncol (1993) 1.39
A phase II study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patients with metastatic melanoma. Cancer Invest (1998) 1.39
Enhancement by recombinant human interferon alfa of the reversal of multidrug resistance by MRK-16 monoclonal antibody. J Natl Cancer Inst (1995) 1.39
Bcl-2 and Bcl-X(L) block thapsigargin-induced nitric oxide generation, c-Jun NH(2)-terminal kinase activity, and apoptosis. Mol Cell Biol (1999) 1.39
You say tomato and I say tomahto: getting a handle on pronouncing apoptosis. J Natl Cancer Inst (1997) 1.39
The role of C3 as an opsonin in the early stages of infection. Proc Soc Exp Biol Med (1975) 1.38
Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil. J Natl Cancer Inst (1995) 1.37
Relationships between cdc2 kinase, DNA cross-linking, and cell cycle perturbations induced by nitrogen mustard. Cell Growth Differ (1992) 1.37
Cell cycle regulation of the human polo-like kinase (PLK) promoter. J Biol Chem (1997) 1.37
Reversal of 2-bromoethanesulfonate inhibition of methanogenesis in Methanosarcina sp. J Bacteriol (1983) 1.35
Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res (1993) 1.34
Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res (1995) 1.33
The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res (1987) 1.32
Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis (1996) 1.32
Mechanistic studies of transforming growth factor-beta inhibition of IL-2-dependent activation of CD3- large granular lymphocyte functions. Regulation of IL-2R beta (p75) signal transduction. J Immunol (1991) 1.31